drugset / Trial / NCT05932264
Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 2, open-label study to evaluate the efficacy and safety of combination of Apatinib and Fluzoparib with or without Adebrelimab in previously-treated TP53-mutant advanced non-small cell lung cancer.
Timeline
- Start
- 2023-07
- Primary completion
- 2024-07
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Fluzoparib | Small molecule | 100 mg | Oral |
| Subject | Rivoceranib | Small molecule | 375 mg | Oral |